Chimeric HLA-A*02:01 (mα3) &mB2M&NY-ESO-1 (SLLMWITQC) Monomer Protein
Catalog No: NYESO1-HP012
- Species
- Human&Mouse
- Expression System
- HEK293
- Tag
- His
- Activity
- Activity verified
Product overview
Recombinant Chimeric HLA-A*02:01 (mα3) &mB2M&NY-ESO-1 (SLLMWITQC) Monomer Protein is expressed from HEK293 with His tag at the C-terminus. It contains Gly25-Thr206 (Human HLA-A*02:01 α1&α2) and Asp207-Glu299 (Mouse H-2Ld α3), Ile21-Met119 (mB2M) and SLLMWITQC peptide (accession: A0A140T913(Human HLA-A*02:01 α1 & α2) & P01897(Mouse H-2Ld α3) & P01887(Mouse B2M) &SLLMWITQC).
Product Details
- Molecular Aliases
- MHC; MY-ESO-1; CT6.1; LAGE-2; CTAG1; CTAG1B; ESO1CTAG; LAGE2A; NY-ESO-1; CTAG1A
- Protein Length
- Gly25-Thr206
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 48.02 kDa. Due to glycosylation, the protein migrates to 50-65 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
- State
- Liquid
- Storage Conditions
- Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Data Display
Chimeric HLA-A*02:01 (mα3) &mB2M&NY-ESO-1 (SLLMWITQC) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Immobilized Anti-HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Antibody, hFc Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Chimeric HLA-A*02:01 (mα3) &mB2M&NY-ESO-1 (SLLMWITQC) Monomer, His Tag with the EC50 of 23.0ng/ml determined by ELISA (QC Test).
Anti-HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Antibody, hFc Tag captured on CM5 Chip via Protein A can bind Chimeric HLA-A*02:01(mα3)&mB2M&NY-ESO-1(SLLMWITQC) Monomer, His Tag with an affinity constant of 9.32 nM as determined in SPR assay (Biacore T200).
Background
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
References
- Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, Decock J. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. Front Immunol. 2018 May 1;9:947. doi: 10.3389/fimmu.2018.00947. PMID: 29770138; PMCID: PMC5941317.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.